Michael Roller - Bioquell plc Insider |
| Bioquell plc -- USA Stock | USD 3.18 0.01 0.31% |
Group Finance Director, Director
Mr. Michael R. D. Roller was appointed as Group Finance Director, Executive Director of the Comapny effective March 18, 2014. He Joined the Board in March 2014. He has previously been Finance Director of a number of quoted companies, most recently Corin Group PLC, has significant experience within the Life Sciences sector and is a non executive director of Filtronic plc. He qualified as an accountant with KPMG.Age: 48 Director Since 2014
44 1264 835 900 http://www.bioquellplc.com
Management Efficiency
The company has return on total asset (ROA) of 5.32 % which means that it generated profit of $5.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 5.16 % meaning that it generated $5.16 on every $100 dollars invested by stockholders.Similar Executives
| Showing few of many executives | DIRECTOR Since | |
| Alfred Ty | Metro Pacific Investments Corpo | 2015 |
| David Nicol | Metro Pacific Investments Corpo | 2010 |
| Albert Rosario | Metro Pacific Investments Corpo | 2016 |
| Antonio Picazo | Metro Pacific Investments Corpo | 2016 |
| Edward Go | Metro Pacific Investments Corpo | 2006 |
| Ramoncito Fernandez | Metro Pacific Investments Corpo | 2009 |
| Robert Nicholson | Metro Pacific Investments Corpo | 2009 |
| Artemio Panganiban | Metro Pacific Investments Corpo | 2007 |
| Ray Espinosa | Metro Pacific Investments Corpo | 2009 |
| Amado Santiago | Metro Pacific Investments Corpo | 2006 |
| Francisco Sebastian | Metro Pacific Investments Corpo | 2016 |
| Rodrigo Franco | Metro Pacific Investments Corpo | 2016 |
| Victorico Vargas | Metro Pacific Investments Corpo | 2011 |
| Edward Tortorici | Metro Pacific Investments Corpo | 2009 |
| Augusto Palisoc | Metro Pacific Investments Corpo | 2006 |
| Lydia Echauz | Metro Pacific Investments Corpo | 2009 |
| Washington Sycip | Metro Pacific Investments Corpo | 2011 |
Entity Summary
Bioquell PLC designs, manufactures, and supplies biodecontamination and containment equipment, and related solutions and services to the pharmaceutical, healthcare, food, and defense industries in the United Kingdom and internationally. Bioquell plc (BIQLF) is traded on OTC Market in USA. It is located in Andover, SP TS and employs 226 people.
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Bioquell plc to your portfolio
Top Management
Bioquell plc Leadership Team
| Ian Johnson, Chairman | |
| Nigel Keen, Chairman | |
| Nicholas Adams, Director | |
| Christopher Mills, Director | |
| Anthony Bourne, Director | |
| Georgina Pope, Executive | |
| Michael Roller, Director | |
| Tony Bourne, Director | |
| Ian Carruthers, Director | |
| Simon Constantine, Director |
Stock Performance
Bioquell plc Performance Indicators
| Return On Equity | 5.16 % | ||
| Return On Asset | 5.32 % | ||
| Profit Margin | 4.49 % | ||
| Operating Margin | 9.27 % | ||
| Current Valuation | 55.33 M | ||
| Price to Earning | 46.15 times | ||
| Price to Book | 2.2 times | ||
| Price to Sales | 1.85 times | ||
| Revenue | 37.95 M | ||
| Gross Profit | 13 M |